We do not wait for certainty to exercise judgment.
An ingredient earns a place when its identity is clear, its biological role is specific, human evidence points in a useful direction, the amount is defensible, and its assignment in the formula is distinct. We are willing to take a position before science is finished—and equally willing to show where the evidence stops.
This approach is more demanding than either extreme. It rejects hype that turns a cell experiment into a guaranteed human outcome, but it also rejects the idea that promising ingredients should be ignored until every possible clinical question has been answered.
Four layers. Four different questions.
Human outcomes
Randomized trials ask whether an intervention changed a defined measure in a defined population.
Highest relevance to outcomesHuman exposure
Pharmacokinetic studies ask whether a form changes circulating concentration, absorption, or persistence.
Strong for form decisionsMechanism
Cell, tissue, and animal work explains pathways, targets, transporters, and biological plausibility.
Strong for ingredient identityFormula logic
Distinct ingredients are assigned complementary jobs without pretending the combination has been clinically proven.
Strong for architectureThe studies shaping our ingredient positions.
NMN
Controlled oral NMN studies have reported increases in blood NAD⁺ or related metabolites, giving the ingredient a direct human-exposure foundation for its longevity-science position.
PQQ
Controlled 12-week studies using approximately 20–21.5 mg daily reported changes across selected cognitive measures in healthy adults. Samples were modest, but the repeated dose range gives PQQ a meaningful human-evidence signal.
PQQ
Cultured mouse liver cells exposed to PQQ showed increases in mitochondrial measures linked to CREB and PGC-1α. This is the mechanistic foundation for PQQ's mitochondrial-renewal position.
Inositol
The review supporting the 2023 international PCOS guideline found signals across selected metabolic outcomes while judging many clinical outcomes uncertain because studies vary in form, dose, and design.
MI + DCI
A seven-ratio comparison reported the strongest results in its 40:1 group. With eight participants per group, it is a formulation signal—not the only reason for choosing the ratio.
Ubiquinol QH
Controlled comparisons have reported higher circulating CoQ10 exposure with ubiquinol than ubiquinone under the studied conditions, supporting a distinct premium-form position.
Ergothioneine
Discovery and characterization of a dedicated human transporter gives ergothioneine an unusually specific cellular-uptake story and a strong mechanistic identity.
Magnesium Bisglycinate
A double-blind trial in adults with poor sleep evaluated 250 mg elemental magnesium as bisglycinate. It adds form-specific human evidence for magnesium bisglycinate in adults with poor sleep.
From paper to product architecture.
Was the studied ingredient the same form used in the formula?
Is the product amount comparable, supportive, or materially different?
Does the ingredient add a distinct biological function?
Say why we chose it and what the evidence lets us believe.
No single paper carries a complete formula. Confidence comes from alignment: a real biological job, evidence in the intended direction, an identifiable form, a disclosed amount, and a reason the ingredient belongs beside the others.
What we look for before we cite a study.
Population
Healthy adults, diagnosed patients, age group, baseline status, and inclusion criteria determine who the result describes.
Intervention
Form, amount, serving pattern, duration, comparator, and co-ingredients must match the claim being considered.
Outcome
A biomarker, questionnaire, cognitive test, blood concentration, and clinical event are not equivalent endpoints.
Study power
Sample size, prespecified analysis, multiple comparisons, dropouts, and replication shape how strongly we interpret a result.
We will not use a curcumin absorption study to prove every black-pepper pairing, a cell-biogenesis study to claim a guaranteed human outcome, or a single-ingredient trial to declare an entire combination clinically proven.
Clinical Evidence FAQs
What counts as clinical evidence?+
Clinical evidence comes from research in humans. Randomized controlled trials, observational studies, pharmacokinetic studies, and systematic reviews answer different kinds of questions and should not be treated as interchangeable.
Does mechanistic evidence matter?+
Yes. Mechanistic evidence explains biological plausibility and helps distinguish ingredients with specific jobs. It does not by itself prove a consumer outcome, but it is central to rational formulation.
Why use an ingredient before evidence is final?+
Nutrition science is rarely finished. We select when ingredient identity, mechanism, human signals, usable dose, safety context, and formula role form a coherent case.
Why does ingredient form matter?+
Different forms can vary in chemical identity, stability, absorption, and studied use. We compare the form named in a paper with the form identified in the formula before applying the evidence.
Why do dose and study duration matter?+
A result is most informative when the amount, serving pattern, and study period are clearly defined. These details help determine how directly the findings can inform an ingredient position.